Compare GWAV & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | ABP |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 18.8M |
| IPO Year | N/A | N/A |
| Metric | GWAV | ABP |
|---|---|---|
| Price | $6.83 | $5.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 123.0K | 27.8K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $32,144,792.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $4.25 | $4.55 |
| 52 Week High | $90.83 | $153.90 |
| Indicator | GWAV | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 57.16 |
| Support Level | $6.46 | $5.41 |
| Resistance Level | $8.50 | $6.19 |
| Average True Range (ATR) | 0.95 | 0.58 |
| MACD | 0.16 | -0.26 |
| Stochastic Oscillator | 57.85 | 32.10 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio and North Carolina. At these facilities, the company is involved in collecting, classifying, and processing raw scrap metal (ferrous and nonferrous) for recycling. The company involves collecting, classifying and processing appliances, construction material, end-of-life vehicles, boats, and industrial machinery and processing those items by crushing, shearing, shredding, separating, and sorting, into smaller pieces and categorize these recycled ferrous, nonferrous, and mixed metal pieces based on density and metal prior to sale.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.